Lazertinib: A Cardio‐Safer Alternative to Osimertinib for Epidermal Growth Factor Receptor L858R/T790M Double‐Mutant Tyrosine Kinase Resistant Non‐Small Cell Lung Cancer

Documenti analoghi

• Flavokawain A: A Natural MAO‐A Inhibitor With Therapeutic Promise for Depression
  di: Vaishnavi Pawa, et al.
  Pubblicazione: (2025)
• Delayed Gastric Bleeding in a Patient With Chronic Myeloid Leukemia: A Case of Post‐Biopsy Bleeding
  di: Yoko Kosaka, et al.
  Pubblicazione: (2026)
• Successful Treatment of Osimertinib Resistance in an EGFR‐Mutant Lung Cancer Patient With a Rare STRN3‐ALK Fusion Using Brigatinib and Osimertinib
  di: Chia‐Yu Kuo, et al.
  Pubblicazione: (2025)
• Osimertinib Efficacy and Safety in Treating Epidermal Growth Factor Receptor Mutation‐Positive Advanced Non–Small‐Cell Lung Cancer: A Meta‐Analysis
  di: Mengmeng Zhao, et al.
  Pubblicazione: (2024)
• TGF ‐β Inhibitor Potentiates Osimertinib‐Induced Anti‐Tumor Immunity in Egfr ‐Mutant Lung Cancer
  di: Tadahiro Kuribayashi, et al.
  Pubblicazione: (2026)